Comex Gold Ends the Week 0.84% Higher at $2644.30 — Data Talk
Front Month Comex Gold for October (new front month) delivery gained $21.90 per troy ounce, or 0.84% to $2644.30 this week
--Up for three consecutive weeks
--Up seven of the past nine weeks
--Today it is down $26.10 or 0.98%
--Largest one day dollar and percentage decline since Friday, Aug. 30, 2024
--Fourth highest close in history
--Snaps a seven session winning streak
--Today's settlement value is the fourth highest this year
--Off 0.96% from its 52-week high of $2669.90 hit Thursday, Sept. 26, 2024
--Up 45.56% from its 52-week low of $1816.60 hit Thursday, Oct. 5, 2023
--Rose 43.08% from 52 weeks ago
--Off 0.96% from its 2024 settlement high of $2669.90 hit Thursday, Sept. 26, 2024
--Up 32.86% from its 2024 settlement low of $1990.30 hit Wednesday, Feb. 14, 2024
--Off 0.96% from its record high of $2669.90 hit Thursday, Sept. 26, 2024
--Month-to-date it is up 6.03%
--Year-to-date it is up $581.90 or 28.21%
All prices are calculated based on the settlement price of the current front month contract.
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 27, 2024 13:52 ET (17:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks